Rosen Law Firm Urges Altimmune Investors to Act Ahead of Class Action Deadline

Rosen Law Firm, a globally recognized legal practice advocating for investor rights, is calling attention to investors of Altimmune, Inc. ALT regarding the upcoming deadline for participating in a securities class action lawsuit. The focus is on individuals who purchased company securities between December 1, 2023, and April 26, 2024. These dates mark the beginning and end of the Class Period within which shareholders are presumed affected.

Class Action Details and Deadline

The lawsuit filed by Rosen Law Firm alleges that Altimmune may have provided misleading business information to the public, thereby violating federal securities laws. Investors who acquired Altimmune, Inc. ALT shares during the Class Period may have experienced financial losses due to potential misrepresentations. Affected shareholders are advised to contact counsel prior to the July 5, 2024 deadline to apply as the primary plaintiff in the class action lawsuit.

Company Profile of Altimmune, Inc.

Altimmune, Inc. ALT operates as a clinical-stage biopharmaceutical company with a focus on developing intranasal vaccines and innovative therapies aimed at addressing liver disease and modulating immune responses. With its headquarters situated in Gaithersburg, Maryland, Altimmune stands at the forefront of medical research in these domains.

Rosen, Law, Altimmune, Securities, Deadline, Investors, Lawsuit, ClassAction